January 26, 2026 — Paris & Global — Abivax SA, the French clinical‑stage biotechnology company, this week publicly dismissed speculation that Eli Lilly & Company has made an acquisition bid for the firm, sending ripples through financial and industry circles. The statement from Abivax’s leadership comes amid heightened investor interest following strong late‑stage clinical data for its lead inflammatory bowel disease (IBD) drug, obefazimod.
Abivax’s Chief Executive, Marc de Garidel, described recent takeover chatter as market “noise” and confirmed that no formal acquisition discussions or offers have taken place, directly addressing market rumors about potential Eli Lilly engagement. According to de Garidel, regulatory and foreign‑investment frameworks in France require a public transaction announcement before formal discussions with authorities, a step that has not occurred.
Market Reaction and Speculation Dynamics
In recent weeks, Abivax’s share price experienced significant volatility, in part driven by takeover speculation tied to its obefazimod program — an oral IBD therapy showing compelling results in late‑stage trials. Investors and analysts have noted the drug’s potential to address a rapidly expanding inflammatory bowel disease market, which industry forecasts estimate could exceed $25 billion in the United States by 2030.
Despite the CEO’s denial of an active bid, analysts continue to point to Abivax’s strategic appeal:
- Phase 3 Catalysts: Obefazimod’s strong induction results and promising safety profile have made Abivax a focus of attention in the IBD innovation landscape.
- Upcoming Data: Follow‑on maintenance data from the drug’s Phase 3 program is expected in mid‑2026, potentially enhancing its valuation and commercial prospects.
- Investor Interest: Major financial firms have maintained positive stances on Abivax’s stock due to its clinical progress and long‑term revenue potential, with some analysts reiterating Buy or Outperform ratings, and price targets reflecting confidence in obefazimod’s future role in IBD treatment.
Strategic Implications
The public denial by Abivax’s CEO serves several strategic functions:
- Clarity for Stakeholders: By addressing speculation clearly, Abivax aims to stabilize market expectations and focus attention on its clinical and commercial roadmap.
- Ongoing Funding Position: Abivax has communicated that it has sufficient funding into late 2027, though continued financing and capital access will be critical to support its global development strategy.
- M&A Narrative: While no formal bid is underway, the situation highlights how late‑stage clinical success can rapidly elevate a biotech company’s visibility among global pharma bidders, even before definitive offers are presented.
About Abivax SA
Abivax is a clinical‑stage biopharmaceutical company dedicated to developing therapies that restore immune homeostasis. Its lead candidate, obefazimod, is an oral small molecule designed to modulate the immune response in inflammatory bowel disease and other chronic inflammatory conditions. The company’s development programs continue to generate scientific and investor interest as key clinical milestones approach.
By
